Leonardo Perales-Guerrero

Dr. Leonardo Perales-Guerrero


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
PMPedro Martínez
Pedro Martínez
LPLeonardo Perales-Guerrero
Leonardo Perales-Guerrero
AGAdolfo Gómez-Quiroz
Adolfo Gómez-Quiroz
BABrenda Berenice Avila-Cardenas
Brenda Berenice Avila-Cardenas
KGKaren Gómez-Portilla
Karen Gómez-Portilla
JAJudith Carolina De Arcos-Jiménez
Judith Carolina De Arcos-Jiménez
Linezolid-non-susceptible Enterococcus faecalis (LNSEf) has emerged as a critical clinical concern worldwide, yet data from Latin American settings remain scarce. This study aimed to investigate the molecular epidemiology and mechanisms underlying LNSEf in a Mexican tertiary care university hospital, focusing on clinical correlates and clonal relationships. A total of 392 non-duplicated E. faecalis isolates were collected over 12 months, of which 24 with minimum inhibitory concentrations ≥4 µg/mL underwent whole-genome sequencing to identify specific resistance determinants (optrA, cfrA, 23S rRNA mutations) and to perform multilocus sequence typing (MLST) and phylogenetic analyses. Of the 392 isolates, 6.12% showed linezolid non-susceptibility, predominantly linked to plasmid- or chromosomally encoded optrA; only two isolates carried cfrA. No mutations were detected in 23S rRNA domain V or ribosomal proteins L3/L4. Clinically, LNSEf strains were associated with immunosuppression, previous surgical interventions, and prolonged hospital stays. Although most LNSEf isolates retained susceptibility to ampicillin, vancomycin, and daptomycin, they exhibited high rates of resistance to other antibiotic classes, particularly aminoglycosides and fluoroquinolones. These findings underscore the emergence of LNSEf in this region, highlighting the need for robust genomic surveillance, strict infection control, and judicious antimicrobial stewardship to curb further dissemination.

12 February 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
AGAdolfo Gómez-Quiroz
Adolfo Gómez-Quiroz
BABrenda Berenice Avila-Cardenas
Brenda Berenice Avila-Cardenas
JAJudith Carolina De Arcos-Jiménez
Judith Carolina De Arcos-Jiménez
LPLeonardo Perales-Guerrero
Leonardo Perales-Guerrero
PMPedro Martínez
Pedro Martínez
Jaime Briseno-RamirezJaime Briseno-Ramirez
Jaime Briseno-Ramirez
Background/Objectives: The rise in multidrug-resistant pathogens complicates UTI management, particularly in empirical therapy. This study aimed to develop and describe a Bayesian hierarchical weighted-incidence syndromic combination antibiogram (WISCA) model to optimize antibiotic selection for adult patients with community-onset UTIs. Methods: A retrospective study was conducted using a Bayesian hierarchical model. Data from microbiology laboratory records and medical databases were analyzed, focusing on age, prior antibiotic exposure, and clinical characteristics. Clinical outcomes, including extended hospital stays and in-hospital mortality, were evaluated before WISCA model development. Unlike traditional antibiograms, a WISCA integrates patient-specific factors to improve antimicrobial coverage estimations. A total of 11 monotherapies and 18 combination therapies were tested against 15 pathogens, with posterior coverage probabilities and 95% highest density intervals (HDIs) used to assess coverage. Results: Inappropriate final antibiotic treatment was associated with worse outcomes. The Bayesian framework improved estimations, particularly for rare pathogen–antibiotic interactions, increasing model applicability in high-resistance settings. Combination regimens showed superior coverage, especially in MDR cases and older adults. Conclusions: This study employed a comprehensive methodological approach for WISCA development, enhancing empirical antibiotic selection by incorporating local resistance data and patient-specific factors in a middle-income Latin American country with a high antimicrobial resistance profile. These findings provide a foundation for future clinical applications and antimicrobial stewardship strategies in high-resistance environments.

3 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PMPedro Martínez
Pedro Martínez
LPLeonardo Perales-Guerrero
Leonardo Perales-Guerrero
AGAdolfo Gómez-Quiroz
Adolfo Gómez-Quiroz
BABrenda Berenice Avila-Cardenas
Brenda Berenice Avila-Cardenas
KGKaren Gómez-Portilla
Karen Gómez-Portilla
JAJudith Carolina De Arcos-Jiménez
Judith Carolina De Arcos-Jiménez
Background: Linezolid-non-susceptible Enterococcus faecalis (LNSEf) has emerged as a critical clinical concern worldwide; however, data from Latin American settings remain scarce. Methods: We investigated 392 non-duplicated E. faecalis isolates collected over 12 months in a Mexican tertiary care hospital. Antimicrobial susceptibility was assessed phenotypically, and 24 isolates with linezolid minimum inhibitory concentrations ≥4 µg/mL underwent whole-genome sequencing. Bioinformatic analyses included multilocus sequence typing (MLST), detection of linezolid resistance mechanisms (optrA, cfrA, 23S rRNA mutations), and phylogenetic reconstruction. Results: Of the 392 isolates, 6.12% demonstrated linezolid non-susceptibility, predominantly associated with plasmid- or chromosomally encoded optrA, with only two isolates harboring cfrA. No mutations were detected in 23S rRNA domain V or ribosomal proteins L3/L4. Clinically, LNSEf isolates were linked to immunosuppression, prior surgical procedures, and extended hospital stays. MLST revealed broad genetic diversity, indicating both clonal expansion and independent acquisitions of resistance. Despite retaining susceptibility to ampicillin, vancomycin, and daptomycin, most LNSEf isolates possessed extensive resistance to other classes of antibiotics, particularly aminoglycosides and fluoroquinolones. Conclusions: LNSEf poses a growing threat in this region, driven largely by optrA. Strengthened genomic surveillance, stringent infection control, and optimized antimicrobial stewardship are vital to contain its spread.